News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase III
Amgen (AMGN)'s Bone Drug Romosozumab Succeeds In Phase III Study 9/2/2015
Allergan (AGN) Shows Off Positive Data from AVYCAZ Phase III Study 9/2/2015
Innocoll, Inc. (INNL) Announces First Patient Dosed In The Xaracoll MATRIX-1 Phase III Study For The Treatment Of Postoperative Pain 9/2/2015
ContraVir Pharmaceuticals To Present At Rodman & Renshaw 17th Annual Global Investment Conference 9/2/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) To Present At Rodman & Renshaw Global Investment Conference 9/2/2015
Gilead (GILD)’s Investigational Fixed-Dose Combination Of Emtricitabine/Tenofovir Alafenamide (F/TAF) Meets Primary 48-Week Objective In Phase III Study 9/2/2015
pSivida (PSDV) Announces Fourth Quarter And Fiscal Year 2015 Financial Results Release Date And Conference Call Information 9/2/2015
Janssen Biotech Inc. (JNJ) Release: U.S. FDA Approves Update Of SIMPONI ARIA (golimumab for infusion) Label To Include Improvement In Both Physical And Emotional Measures Of Health When Treating Moderately To Severely Active Rheumatoid Arthritis 9/2/2015
CEL-SCI (CVM) Reports August Patient Enrollment For Its Phase 3 Head And Neck Cancer Trial 9/2/2015
Bayer (BAY) Moves to Phase III Studies After Finerenone Cuts Deaths in Mid-Stage Trial 9/1/2015
BPL Announces Enrollment Of The First Subject In A Phase III Clinical Trial To Evaluate A New Subcutaneous Immunoglobulin Product For Patients With Primary Immunodeficiency 9/1/2015
Boehringer Ingelheim Release: New Analysis Shows Idarucizumab Enables Rapid Initiation Of Emergency Surgery In Dabigatran-Treated Patients 9/1/2015
OSE Pharma Sets Up Scientific Steering Committee And Takes A First Step In The Launch Of Its Phase 3 Trial In Lung Cancer 9/1/2015
ERYtech Pharma Appoints Eric Soyer As Chief Financial And Chief Operating Officer 9/1/2015
FDA Approves Initiation Of ViroMed's VM202 For Phase III Clinical Study Of Chronic Non-Healing Ischemic Diabetic Foot Ulcer 9/1/2015
CytRx Corporation (CYTR) Announces Participation At FBR & Co. Second Annual Health Conference And Rodman & Renshaw 17th Annual Global Investment Conference 9/1/2015
Michael Meyers, M.D., Ph.D., Joins Syndax As SVP And Chief Development Officer 9/1/2015
Janssen Pharmaceuticals, Inc. Release: New Global Real-World Data From Atrial Fibrillation Studies Confirm The Safety Profile Of XARELTO 9/1/2015
Nektar Therapeutics (NKTR) Announces Receipt Of $40 Million Milestone Payment Resulting From First Commercial Sale Of MOVENTIG (naloxegol) Tablets In Major European Market 9/1/2015
Chiasma Reports Second Quarter 2015 Financial Results And Recent Business Highlights 9/1/2015
Can-Fite BioPharma (CFBI) To Present At Rodman & Renshaw 17th Annual Global Investment Conference On September 9, 2015 9/1/2015
Agile Therapeutics, Inc. Announces Completion Of Patient Recruitment In Twirla Phase III SECURE Clinical Trial 9/1/2015
Regeneron (REGN) And Sanofi (SNY) Announce New Positive Praluent (alirocumab) Phase 3 Data Presented At ESC Congress 2015 9/1/2015
XTL Biopharmaceuticals Ltd. (XTLB) Reports Second Quarter 2015 Results 9/1/2015
Marathon Pharmaceuticals, LLC Release: Recently Published Study Shows Positive Results For Zingo In Pediatric Patients 9/1/2015
TiGenix's Cx601 Meets Primary Endpoint in Phase III Study 8/31/2015
Eisai Company (ESALY.PK) And Purdue Pharma L.P. Enter Worldwide Collaboration To Develop And Commercialize Lemborexant 8/31/2015
Telesta Receives FDA BLA Filing Notification Letter And Priority Review Designation For MCNA(1) 8/31/2015
NeuroVive Discontinues Ciclomulsion for Myocardial Infarction 8/31/2015
Vital Therapies (VTL) Announces Additional Data From VTI-208 Presented At Rostock Conference 8/31/2015
Resverlogix (RVX.TO) Presents New Data At The European Society of Cardiology Congress 2015 On RVX-208 'Apabetalone' A Selective BET Inhibitor 8/31/2015
BioMarin (BMRN) Announces Two Oral And 19 Poster Presentations At The Society For The Study Of Inborn Errors Of Metabolism 2015 Annual Meeting 8/31/2015
Piramal Imaging Announces Publication Of Phase III Neuraceq (florbetaben F18) PET Imaging Data In Alzheimer's & Dementia 8/31/2015
Ipsen (IPN.PA) Announces The Lancet Neurology Publishes Dysport Phase III Registration Trial Results In Adult Patients With Upper Limb Spasticity (ULS) 8/31/2015
Ipsen (IPN.PA) Announces Publication In The Lancet Neurology Of The Results Of The Phase III Randomized Study (NCT01313299) Showing Efficacy And Safety Of Dysport (Abobotulinumtoxina) In Adult Patients With Upper Limb Spasticity (ULS) 8/31/2015
Can-Fite BioPharma (CFBI) Reports Financial Results For Six Months Ended June 30, 2015 8/28/2015
Novo Nordisk A/S (NVO) Pulls the Plug on Expanding Victoza for Type 1 Diabetes 8/27/2015
Veloxis Pharmaceuticals A/S (VELO) Announces Financial Results For The First Six Months Of 2015 And Improves The Full Year Outlook 8/27/2015
DelMar Pharmaceuticals To Announce Fiscal 2015 Year-End Financial Results On September 4, 2015 8/27/2015
Symbiomix Completes Enrollment In Second Pivotal Trial Of SYM-1219 For Bacterial Vaginosis, And Receives FDA Fast Track Designation 8/27/2015
PRANA Biotechnology (PRAN) Reports FY15 Financial Results 8/27/2015
Gilead (GILD) Release: Results From The AMBITION Study Of First-Line Treatment With Letairis And Tadalafil In Pulmonary Arterial Hypertension Published In The New England Journal of Medicine 8/27/2015
Lexicon Pharma (LXRX) Announces Telotristat Etiprate Data To Be Presented At European Cancer Congress 8/26/2015
Emisphere Technologies, Inc. (EMIS) Highlights Eligen Licensee Novo Nordisk A/S (NVO)'s Entry Into Phase IIIa Development Of Oral Semaglutide, A Once Daily Oral GLP-1 8/26/2015
Alliance Foundation Trials And Austrian Breast & Colorectal Cancer Study Group Open Largest Global Phase 3 Trial Of Targeted Therapy, IBRANCE (Palbociclib), For Patients With Hormone Receptor–Positive Early Breast Cancer 8/26/2015
SoCal's Vital Therapies (VTL) Tanks as Liver Therapy Fails Phase III Trial 8/25/2015
FDA Grants Orphan Drug Designation For Tocagen Inc.'s Toca 511 & Toca FC, An Investigational Immuno-Oncology Treatment For Glioblastoma 8/25/2015
FDA And European Medicines Agency Accept Regulatory Applications For Boehringer Ingelheim's Gilotrif (afatinib) For Treatment Of Advanced Squamous Cell Carcinoma Of The Lung 8/25/2015
Allergan (AGN) And Gedeon Richter Ltd. (RIG2.F) To Present Data From Cariprazine Trials At European College Of Neuropsychopharmacology (ECNP) Annual Meeting In Amsterdam 8/25/2015
Ascendis Pharma A/S Reports Second Quarter 2015 Financial Results 8/25/2015
CSL Behring Enrolls First Patient In Global Phase II/III Study Of rVIIa-FP For On-Demand Treatment Of Patients With Hemophilia A Or B With Inhibitors 8/25/2015
Amgen (AMGN) To Present New Long-Term Repatha (Evolocumab) Data Analysis At ESC Congress 2015 8/25/2015
Highland Therapeutics Announces Initiation Of Second Pivotal Trial Of HLD-200 In Pediatric ADHD Patients 8/25/2015
Revitalized Exelixis (EXEL) Grabs Breakthrough Tag for Cabozantinib 8/25/2015
NW Bio (NWBO) Temporarily Halts Patient Screening for DCVax-L Brain Cancer Study 8/24/2015
Pfizer (PFE)'s Trumenba Met All Primary Immunogenicity Endpoints in Two Phase III Studies 8/24/2015
Cardiome Pharma Corp. (COM.TO) Expands Partnership With Eddingpharm (Cayman) Inc. To Commercialize AGGRASTAT In China 8/24/2015
Celator Pharmaceuticals, Inc. Appoints Michael R. Dougherty As Executive Chairman Of Board Of Directors 8/24/2015
Esperance Pharmaceuticals, Inc. Announces Strategic Alliance With MD Anderson Cancer Center 8/24/2015
Bristol-Myers Squibb (BMY) And Pfizer (PFE) To Present New Data On Eliquis (apixaban) At The ESC Congress 2015 8/24/2015
Eisai Company (ESALY.PK) Release: FYCOMPA (perampanel) CIII Demonstrates A Significant Reduction In Primary Generalized Tonic-Clonic (PGTC) Seizure Frequency In Phase 3 Trial Of Patients With Epilepsy Age 12 And Older 8/24/2015
Portage Biotech's Biohaven's Lead Drug Candidate Clears FDA Investigational New Drug Application (IND) Review And Clinical Studies To Begin 8/24/2015
Galena Biopharma  (GALE) Announces Independent Data Safety Monitoring Committee Recommends Reduction Of Cardiac Toxicity Monitoring For Neuvax PRESENT Trial 8/24/2015
Collegium (COLL) Publishes Data From Xtampza ER Phase III Clinical Trial In The Journal PAIN 8/24/2015
Halozyme (HALO) Appoints Michael J. Labarre As Chief Scientific Officer 8/24/2015
Exelixis (EXEL) Release: Data From METEOR Pivotal Trial Of Cabozantinib In Advanced Renal Cell Carcinoma Accepted As Late-Breaker Presentation In Presidential Session At European Cancer Congress 2015 8/24/2015
TiGenix Announces Cx601 Meets Primary Endpoint In Pivotal Phase III Trial 8/24/2015
ImmunoCellular Therapeutics, Ltd (IMUC) Issues Letter To Shareholders, Highlighting Progress On Advancing ICT-107 To Phase 3 Registrational Trial 8/21/2015
Macrocure (MCUR) Sinks as CureXcell Flunks Phase III Study 8/20/2015
DelMar Pharmaceuticals Completes $2.6 Million Registered Direct Offering 8/20/2015
PharmaMar Announces License Agreement With Specialised Therapeutics Australia Pty For APLIDIN (plitidepsin) In Oncology 8/20/2015
VBL Therapeutics (VBLX) Announces First Patient Dosed In Pivotal Phase III Trial Of VB-111 In Recurrent Glioblastoma 8/20/2015
BioMarin (BMRN) Receives Rare Pediatric Disease Designation From FDA For Drisapersen For The Potential Treatment Of Duchenne Muscular Dystrophy 8/20/2015
Dipexium Pharmaceuticals (DPRX) Surpasses Treatment Of 50% Of Subjects In Pivotal Phase 3 Clinical Trial 8/20/2015
Charleston Laboratories, Inc. Announces Completion Of A Second Phase 3 Clinical Trial On Its Lead Product, CL-108, And The Appointment Of Dr. Raymond Dionne To Its Scientific Advisory Board 8/20/2015
SELLAS Life Sciences Expands And Strengthens Leadership Team 8/19/2015
LEO Pharma Release: New Study Investigating The Effect Of Low-Molecular-Weight Heparins On The Treatment Of Blood Clots In Cancer Patients 8/19/2015
Intarcia Announces New Top-Line Phase III Results For Investigational Therapy ITCA 650 In Type 2 Diabetes 8/19/2015
Astex Pharmaceuticals (ASTX) Announces Publication Of Key Clinical Data For Guadecitabine (SGI-110) In The Lancet Oncology 8/19/2015
Boehringer Ingelheim Release: CHMP Recommends Label Update For Giotrif With Addition Of Data Demonstrating Overall Survival Benefit For Patients With EGFR Mutation-Positive Lung Cancer 8/19/2015
Palatin Technologies (PTN) Supports FDA's Approval Of The First-Ever Treatment For Female Sexual Dysfunction 8/19/2015
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Published Data Show STIOLTO RESPIMAT Provides Clinically Meaningful Improvements In COPD Health-Related Quality Of Life Measure 8/18/2015
Armetheon Expands Leadership Team, Names Detlef Albrecht, M.D., As Chief Medical Officer 8/18/2015
Tenax Therapeutics (TENX) Announces Nomination Of James Mitchum To Board Of Directors 8/18/2015
Kuros Biosurgery AG Announces The Successful Closing Of A CHF 15 Million Financing Round 8/18/2015
Swedish Orphan Biovitrum Release: Results From B-YOND Study Reinforce Long-Term Clinical Profile Of Alprolix For The Treatment Of Haemophilia B 8/18/2015
Did Merck & Co. (MRK) and NewLink Genetics (NLNK) Just Cure Ebola? 8/17/2015
Mesoblast (MSB.AX) Reports 2015 Financial Year Results And Provides Update On Phase III Chronic Heart Failure Program 8/17/2015
SAGE Therapeutics (SAGE) Announces First Patient Treated In Phase III STATUS Trial Of SAGE-547 In Super-Refractory Status Epilepticus 8/17/2015
Xbiotech Completes Enrollment For Xilonix Phase III Registration Study In Europe 8/17/2015
Chiasma Announces FDA Acceptance For Filing Of New Drug Application For Octreotide Capsules In Acromegaly 8/17/2015
R-PHARM Acquires IXEMPRA (Ixabepilone) From Bristol-Myers Squibb (BMY) And Launches U.S. Commercial Operations 8/17/2015
Clinical Data From Merz Neurosciences’ Phase III Study Of Xeomin® (Incobotulinumtoxina) For Spasticity To Be Published In “Muscle & Nerve” 8/17/2015
Spectrum Pharmaceuticals, Inc. (SPPI) Announces Agreement With FDA On The Special Protocol Assessment (SPA) For The Upcoming Apaziquone Phase 3 Trial In Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) 8/17/2015
Biogen (BIIB) Release: Results From B-YOND Extension Study Reinforce Long-Term Clinical Profile Of ALPROLIX For The Treatment Of Hemophilia B 8/17/2015
Boehringer Ingelheim Release: New Data Show Spiolto Respimat Provides Meaningful Quality Of Life Improvements In COPD 8/17/2015
OncoGenex Pharmaceuticals Inc. (OGXI) Reports Financial Results For Second Quarter 2015 8/14/2015
AEterna Zentaris (AEZS) Second Quarter Financial And Operating Results 8/14/2015
Sophiris Bio Inc. (SPHS) Reports Second Quarter Financial Results 8/14/2015
Evoke Pharma, Inc. Reports Second Quarter 2015 Results 8/14/2015
Dermira Reports Second Quarter 2015 Financial Results And Provides Corporate Update 8/14/2015
Bellerophon Therapeutics (BLPH) Reports 2015 Second Quarter Operational And Financial Results 8/14/2015
Immunomedics, Inc. (IMMU) Announces Conference Call And Webcast For Fourth Quarter And Fiscal Year 2015 Financial Results 8/14/2015
Innocoll, Inc. (INNL) Announces Second Quarter 2015 Financial And Operating Results And Updates Late-Stage Product Portfolio Progress 8/14/2015
Titan Pharmaceuticals (TTP) Reports Second Quarter 2015 Financial Results 8/14/2015
ImmunoCellular Therapeutics, Ltd (IMUC) Reaches Agreement With FDA On Special Protocol Assessment (SPA) For ICT-107 Phase 3 Registrational Trial In Glioblastoma 8/13/2015
Alimera Sciences (ALIM) Signs Exclusive ILUVIEN Distributor For Italy, San Marino And Vatican City 8/13/2015
Neurocrine Biosciences (NBIX) Announces Completion Of Enrollment Into Kinect 3 Tardive Dyskinesia Study 8/13/2015
CrystalGenomics Partners With Dong-A ST For Acelex Commercialization In Korea 8/13/2015
Pfenex (PFNX) Reports Second Quarter 2015 Results And Provides Business Update 8/13/2015
Tokai Pharmaceuticals (TKAI) Reports Second Quarter 2015 Results 8/13/2015
NephroGenex (NRX) Reports Second Quarter 2015 Financial Results 8/13/2015
Eleven Biotherapeutics (EBIO) Reports Second Quarter 2015 Financial Results 8/13/2015
CoLucid Pharma Announces Second Quarter 2015 Results And Corporate Highlights 8/13/2015
Aradigm Corporation (ARDM) Announces Second Quarter 2015 Financial Results 8/13/2015
Argos Therapeutics, Inc. (ARGS) Reports Second Quarter 2015 Financial Results And Operational Highlights 8/13/2015
Collegium (COLL) Reports Second Quarter Financial Results And Provides Corporate Update 8/13/2015
Otonomy (OTIC) Reports Second Quarter 2015 Financial Results And Provides Corporate Update 8/13/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: New Publication Elaborates On TB4's Effects On Dry Eye Syndrome And Other Potential Ophthalmic Disorders 8/12/2015
Celator Pharmaceuticals, Inc. Announces Second Quarter 2015 Financial Results And Business Update 8/12/2015
Axovant (AXON) Reports Financial Results For The First Fiscal Quarter Of 2015 And Provides Corporate Update 8/12/2015
Ardelyx (ARDX) Reports Second Quarter 2015 Financial Results 8/12/2015
Soligenix (SNGX) Announces Recent Highlights and Second Quarter 2015 Financial Results 8/12/2015
RedHill Biopharma Ltd. (RDHL) To Present RHB-104 Phase III Crohn's Program At The International Research Symposium On Crohn's Disease 8/12/2015
Proteon Therapeutics, Inc. (PRTO) Initiates Second Phase III Clinical Study Of Investigational Drug Vonapanitase 8/12/2015
InSite Vision (ISV) Reports Second Quarter 2015 Financial Results 8/12/2015
Eleven Biotherapeutics (EBIO) Announces First Patients Dosed With EBI-005 In Phase 3 Study In Patients With Moderate To Severe Allergic Conjunctivitis 8/12/2015
Exelixis (EXEL) Announces Second Quarter 2015 Financial Results And Provides Corporate Update 8/12/2015
Dyax Corp. (DYAX) Provides Update On DX-2930 Clinical And Commercial Supply Initiatives 8/12/2015
Akebia Therapeutics, Inc. (AKBA) Announces Second Quarter 2015 Financial Results 8/12/2015
Ischemix Elects Peter G. Milner, MD To Board Of Directors 8/12/2015
Theravance Biopharma, Inc. Reports Second Quarter 2015 Financial Results And Provides Business Update 8/12/2015
Zafgen (ZFGN) Reports Second Quarter 2015 Financial Results 8/12/2015
Zosano Reports Second Quarter 2015 Financial Results 8/12/2015
Histogenics Corporation Announces Second Quarter 2015 Financial And Operating Results 8/12/2015
SAGE Therapeutics (SAGE) Announces Second Quarter 2015 Financial Results And Highlights Recent Progress 8/12/2015
ARCA biopharma Announces Second Quarter 2015 Operating Results And Provides Update On Recent Accomplishments 8/12/2015
Halozyme (HALO) Reports Second Quarter 2015 Financial Results 8/11/2015
Alimera Sciences (ALIM) Reports Second Quarter 2015 Financial Results 8/11/2015
Discovery Laboratories (DSCO) Provides Business Update And Reports Second Quarter 2015 Financial Results 8/11/2015
US Army And Helius Medical Technologies Announce Launch Of Phase III Traumatic Brain Injury Clinical Trial 8/11/2015
Ocular Therapeutix (OCUL) Reports Second Quarter 2015 Financial Results 8/11/2015
Puma Biotech (PBYI) Reports Second Quarter 2015 Financial Results 8/11/2015
AEterna Zentaris (AEZS) Announces Data And Safety Monitoring Board Scheduled To Complete Second Interim Analysis Of The ZoptEC Phase 3 Trial In Endometrial Cancer In Early October 8/11/2015
Synergy Pharma Reports Second Quarter And First Half 2015 Financial Results And Business Update 8/11/2015
Trevena, Inc. (TRVN) Reports Second Quarter 2015 Financial Results And Provides A Corporate Update 8/11/2015
Zogenix (ZGNX) Provides Corporate Update And Reports Second Quarter 2015 Financial Results 8/11/2015
Coherus Reports Second Quarter 2015 Financial And Operating Results 8/11/2015
Intec Pharma Ltd. Announces Closing of U.S. Initial Public Offering 8/10/2015
BioDelivery Sciences International (BDSI) Provides Corporate Update And Reports Second Quarter 2015 Financial Results 8/10/2015
Axsome Announces Enrollment Of The First Patient In A Phase III Trial Of AXS-02 For Complex Regional Pain Syndrome (CRPS) 8/10/2015
Celsion Corporation (CLSN) And myTomorrows Expand ThermoDox European Early Access Program To Include Patients With Primary Liver Cancer And Liver Cancer Metastases 8/10/2015
Celsion Corporation (CLSN) Reports Second Quarter 2015 Financial Results And Provides Business Update 8/10/2015
CEL-SCI (CVM) Reports Third Quarter Fiscal Year 2015 Financial Results 8/10/2015
Antares Pharma, Inc. (ATRS) Reports Second Quarter 2015 Operating And Financial Results 8/10/2015
Horizon Pharma (HZNP) Announces Record Second Quarter 2015 Financial Results 8/10/2015
Gamida Cell Achieves Major Regulatory Milestone: FDA And European Medicines Agency Respond Positively to NiCord Phase III Study Design Outline 8/10/2015
AVEO Oncology (AVEO) Reports Second Quarter 2015 Financial Results 8/10/2015
Argos Therapeutics, Inc. (ARGS) Announces Pilot Clinical Trial Of AGS-003 As Neoadjuvant Immunotherapy For Localized Renal Cell Carcinoma 8/10/2015
GlycoMimetics, Inc. (GLYC) Reports Second Quarter 2015 Results 8/7/2015
ImmunoCellular Therapeutics, Ltd (IMUC) Announces Second Quarter 2015 Financial Results 8/7/2015
Lexicon Pharma (LXRX) Reports 2nd Quarter Financial Results, Provides Clinical Pipeline Update 8/7/2015
NephroGenex (NRX) To Host Conference Call And Webcast On Second Quarter 2015 Financial Results On Thursday, August 13, 2015 8/7/2015
bluebird bio (BLUE) Reports Second Quarter 2015 Financial Results And Recent Operational Progress 8/7/2015
Cytori Therapeutics, Inc. (CYTX) Reports Second Quarter 2015 Business and Financial Results 8/7/2015
XBiotech USA (XBIT) Announces Expansion Of Global Phase III Registration Study In Europe Using Xilonix For Treatment Of Metastatic Colorectal Cancer 8/7/2015
Flexion (FLXN) Reports Second-Quarter 2015 Financial Results 8/7/2015
Inotek Pharmaceuticals Corporation Reports Second Quarter 2015 Financial Results And Operational Highlights 8/7/2015
Tesaro, Inc. (TSRO) Announces Second-Quarter 2015 Operating Results 8/7/2015
La Jolla Pharma (LJPC) Announces Second Quarter 2015 Financial Results And Recent Corporate Progress 8/7/2015
TiGenix Obtains FDA's Endorsement Through Special Protocol Assessment For Its Cx601 Phase III Registration Trial In The US 8/7/2015
Galena Biopharma  (GALE) Reports Second Quarter 2015 Financial Results 8/7/2015
Medivation, Inc. (MDVN) Reports Second Quarter 2015 Financial Results 8/7/2015
Esperion Therapeutics (ESPR) Provides ETC-1002 Development Program Update; Reports Second Quarter 2015 Financial Results 8/7/2015
CTI BioPharma Reports Second Quarter 2015 Financial Results 8/7/2015
Spectrum Pharmaceuticals, Inc. (SPPI) Reports Second Quarter 2015 Financial Results And Pipeline Update 8/7/2015
Alnylam (ALNY) Reports Second Quarter 2015 Financial Results And Highlights Recent Period Activities 8/7/2015
Anacor (ANAC) Reports Second Quarter 2015 Financial Results 8/7/2015
Heron (HRTX) Announces Second Quarter 2015 Financial Results And Recent Corporate Progress 8/7/2015
Synta (SNTA) Reports Second Quarter 2015 Financial Results 8/6/2015
Acceleron Pharma Reports Second Quarter 2015 Financial And Operational Results 8/6/2015
Aerie (AERI) To Present At The Canaccord Genuity Growth Conference 8/6/2015
Infinity Pharmaceuticals Inc. (INFI) Provides Company Update And Reports Second Quarter 2015 Financial Results 8/6/2015
Acadia (ACAD) Announces Publication Of Data From Its -015 Open Label Safety Study In Parkinson’s Disease Psychosis In The Journal Of The American Medical Directors Association 8/6/2015
Enrollment Begins In Cytori Therapeutics, Inc. (CYTX) U.S. Phase III/Pivotal Scleroderma Trial 8/6/2015
Intersect ENT Reports Second Quarter 2015 Results 8/6/2015
Orexigen (OREX) And Takeda (TKPYY) Announce An Amended And Restated Collaboration Agreement 8/6/2015
Celsion Corporation (CLSN) Announces Updated Overall Survival Data From HEAT Study Of ThermoDox In Primary Liver Cancer 8/6/2015
CytoDyn Initiates First Clinical Site For Phase III Trial Of PRO 140 8/6/2015
Jazz Pharmaceuticals (JAZZ) Announces Second Quarter 2015 Financial Results 8/6/2015
Nektar Therapeutics (NKTR) Reports Financial Results For The Second Quarter Of 2015 8/6/2015
Nuvo Research Inc. (NRI.TO) Announces 2015 Second Quarter Results 8/6/2015
Orexigen (OREX) Reports Financial And Business Results For The Second Quarter Ended June 30, 2015 8/6/2015
GW Pharma (GWPH) Reports Third Quarter 2015 Financial Results And Operational Progress 8/6/2015
GW Pharma (GWPH) Receives FDA Fast Track And European Medicines Agency Orphan Designations For Intravenous Cannabidiol In The Treatment Of Neonatal Hypoxic-Ischemic Encephalopathy (NHIE) 8/6/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) Provides Update On Clinical Trials In U.S., Korea And China 8/6/2015
Opko Health (OPK) Announces Second Quarter Operating And Financial Results 8/6/2015
Orexigen (OREX) Announces Korean Distributorship Agreement with Kwang Dong Pharmaceutical 8/6/2015
Ironwood (IRWD) Provides Second Quarter 2015 Investor Update 8/6/2015
SAGE Therapeutics (SAGE) Receives Special Protocol Assessment For Phase III STATUS Trial Of SAGE-547 In Super-Refractory Status Epilepticus 8/6/2015



//-->